Open AccessOutcome in pediatric acute lymphoblastic leukemia in children and adolescents using contemporary protocols of chemotherapy – experience of a single Pediatric Hematology-Oncology Center
Author(s) -
Claudia Diţă,
Anca Coliţă,
Mirela Asan,
Anca Gheorghe,
Cerasela Jardan,
Mihaela Dragomir,
C Arion
Publication year - 2015
Publication title -
romanian journal of medical practice
Language(s) - English
Resource type - Journals
eISSN - 2069-6108
pISSN - 1842-8258
DOI - 10.37897/rjmp.2015.4.9
Subject(s) - medicine , pediatric oncology , hematology , minimal residual disease , immunophenotyping , chemotherapy , lymphoblastic leukemia , single center , cohort , pediatrics , oncology , leukemia , cancer , immunology , flow cytometry
The authors studied the outcome of a cohort of pediatric acute lymphoblastic leukemia (ALL) patients (33 children and adolescence) diagnosed and treated conforming to modern Chemotherapy Protocols (ALL ICBFM 2002, Interfant 06) in a single Center – Pediatric Clinic, Fundeni Clinical Institute, Bucharest, Romania. They analyzed the factors which determine the prognosis and the outcome of these patients in the course of multi-agent systemic chemotherapy to stand at the base of these Protocols: initial age, initial leukocyte count, blasts immunophenotype, cytogenetic and molecular abnormalities, initial response to cortisone, risk groups, time to obtain the complet remission, etc. Among the factors they discussed, a great value was proven to have the minimal residual disease (MRD) determination in certain check points of Protocols and revaluation of patients risk conforming to MRD values. Using the modern Protocols and continuously watching the evolution on therapy enable the authors to obtain results close to those of European and North American Pediatric Hematology Oncology Centers: OS 90.9% by 40 Mo and EFS 72.7% at the end of the same period of time.